Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
1(17%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_3
2
33%
Ph phase_1
3
50%

Phase Distribution

3

Early Stage

0

Mid Stage

2

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
3(60.0%)
Phase 3Large-scale testing
2(40.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

6

all time

Status Distribution
Active(4)
Completed(2)

Detailed Status

Not yet recruiting3
Completed2
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
1
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 13 (60.0%)
Phase 32 (40.0%)

Trials by Status

completed233%
recruiting117%
not_yet_recruiting350%

Recent Activity

1 active trials
Showing 5 of 6
not_yet_recruitingphase_1

A Study to Compare the PK , Safety, and Immunogenicity of QL2109 With Daratumumab in Male Subjects

NCT07400744
not_yet_recruitingphase_3

A Study to Evaluate the Efficacy and Safety of HLX15-IV Versus DARZALEX® in Combination with Lenalidomide-Dexamethasone (Rd) in Transplant-ineligible Patients with Newly Diagnosed Multiple Myeloma

NCT06895512
not_yet_recruitingphase_1

Escalation of Doses of Daratumumab in Combination With Chemotherapy (Idarubicin and Cytarabine) in Patients of 60 Years Old or More With Adverse Risk Acute Myeloblastic Leukemia (AML) (DARALAM)

NCT05749276
completed

Daratumumab Provided at Home Experience An Open, Single-center, Mixed-method Project.

NCT05306587
recruitingphase_3

A Study of the Efficacy and Safety of Monotherapy With BCD-264 and Darzalex in Subjects With Relapsed and Refractory Multiple Myeloma

NCT06296121
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT07400744Phase 1

A Study to Compare the PK , Safety, and Immunogenicity of QL2109 With Daratumumab in Male Subjects

Not Yet Recruiting
NCT06895512Phase 3

A Study to Evaluate the Efficacy and Safety of HLX15-IV Versus DARZALEX® in Combination with Lenalidomide-Dexamethasone (Rd) in Transplant-ineligible Patients with Newly Diagnosed Multiple Myeloma

Not Yet Recruiting
NCT05749276Phase 1

Escalation of Doses of Daratumumab in Combination With Chemotherapy (Idarubicin and Cytarabine) in Patients of 60 Years Old or More With Adverse Risk Acute Myeloblastic Leukemia (AML) (DARALAM)

Not Yet Recruiting
NCT05306587

Daratumumab Provided at Home Experience An Open, Single-center, Mixed-method Project.

Completed
NCT06296121Phase 3

A Study of the Efficacy and Safety of Monotherapy With BCD-264 and Darzalex in Subjects With Relapsed and Refractory Multiple Myeloma

Recruiting
NCT05974969Phase 1

A Study to Assess the PK, PD, Safety and Immunogenicity of Single IV Infusion of BCD-264 and Darzalex in Healthy Subjects

Completed

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6